# Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

> **NCT03381625** · PHASE2 · COMPLETED · sponsor: **BioMimetix JV, LLC** · enrollment: 139 (actual)

## Conditions studied

- Psoriasis
- Atopic Dermatitis

## Interventions

- **DRUG:** BMX-010
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03381625
- **Lead sponsor:** BioMimetix JV, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-02
- **Primary completion:** 2021-07-24
- **Final completion:** 2021-07-24
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2021-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03381625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03381625, "Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03381625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*